A CRA expert was retained in an antitrust matter involving patent settlement agreements between branded and generic pharmaceutical manufacturers that involved so-called ‘reverse payments’. Plaintiffs alleged that the agreements involved a conspiracy to fix prices and allocate markets, and that this conspiracy involved an exclusionary scheme to maintain a monopoly. CRA’s expert determined that generic versions of the drug would not likely have entered earlier absent the settlement agreements, the relevant market included competing branded products, and the agreements were not anticompetitive.
CRA nominated for five articles in 2025 Antitrust Writing Awards by Concurrences
The CRA articles ranked among the impressive academic and business article submissions to the Concurrences Editorial Committee, which received a combined total...